doi: 10.1006/viro.1996.0239.
A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier
Affiliations
- PMID: 8623532
- DOI: 10.1006/viro.1996.0239
Item in Clipboard
A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier
Virology.
.
Free article
Abstract
In this manuscript, an E1 and E3 deleted adenoviral recombinant expressing the rabies virus glycoprotein (G protein) under the control of the cytomegalovirus early promoter was tested for induction of a rabies virus-specific immune response in mice. The construct was found to induce neutralizing antibodies and cytolytic T cells to rabies virus. Mice vaccinated with the adenoviral construct either by the systemic route or by application into the airways were protected against a subsequent infection with a virulent strain of rabies virus. The efficacy of the replication-defective construct was far superior to that of a well-characterized vaccinia rabies glycoprotein recombinant.
Similar articles
-
[Recombinant replication-defective adenovirus based rabies vaccine].Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Dec;25(6):650-4. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003. PMID: 14714304 Chinese.
-
Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.Virology. 1994 Feb 15;199(1):132-40. doi: 10.1006/viro.1994.1105. Virology. 1994. PMID: 8116236
-
Immune responses to nucleic acid vaccines to rabies virus.Virology. 1995 Jun 1;209(2):569-79. doi: 10.1006/viro.1995.1289. Virology. 1995. PMID: 7778289
-
Canine adenovirus based rabies vaccines.Dev Biol (Basel). 2008;131:467-76. Dev Biol (Basel). 2008. PMID: 18634509 Review.
-
Target and non-target effects of a recombinant vaccinia-rabies virus developed for fox vaccination against rabies.Dev Biol Stand. 1995;84:183-93. Dev Biol Stand. 1995. PMID: 7796953 Review. No abstract available.
Cited by
-
Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines.Viruses. 2012 Nov 1;4(11):2711-35. doi: 10.3390/v4112711. Viruses. 2012. PMID: 23202501 Free PMC article. Review.
-
Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.J Clin Invest. 2015 Mar 2;125(3):1129-46. doi: 10.1172/JCI78280. Epub 2015 Feb 2. J Clin Invest. 2015. PMID: 25642773 Free PMC article.
-
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.J Virol. 2005 Jan;79(2):771-9. doi: 10.1128/JVI.79.2.771-779.2005. J Virol. 2005. PMID: 15613305 Free PMC article.
-
Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.J Virol. 2003 Sep;77(18):10078-87. doi: 10.1128/jvi.77.18.10078-10087.2003. J Virol. 2003. PMID: 12941918 Free PMC article.
-
Long-Term Immunogenicity and Efficacy of the Oral Rabies Virus Vaccine Strain SPBN GASGAS in Foxes.Viruses. 2019 Aug 27;11(9):790. doi: 10.3390/v11090790. Viruses. 2019. PMID: 31461981 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
